Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVESEC Trial
NCT07460245Phase 2Not yet recruiting
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jun 2026
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in urothelial carcinoma (UC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
avelumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07460245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07460245.